Blood tests for immunotherapy in blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at blood samples from people with blood cancers to find markers that might predict how well immunotherapy will work. The goal is to help doctors choose the right treatment for each person.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a blood cancer (like leukemia, lymphoma, or myeloma) that your doctor thinks may be helped by immunotherapy.
- The study needs blood or bone marrow samples taken before you start a new treatment line or before an autologous (your own) stem cell transplant.
- If you are between treatment lines or before a transplant, you must have been off chemotherapy for at least 4 weeks.
- You need to be covered by a social security scheme (like French health insurance).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for markers of cancer in your blood. It may help doctors learn more about your tumor and how to treat it.
This study collects extra blood samples during your routine care to look for markers that might help predict how well cancer treatments work and how long people live. Participating involves no extra procedures beyond what you already need.
This trial looks at blood samples to measure substances that may reflect cancer (tumor markers). It may help doctors understand cancer better and improve future monitoring, as long as you can safely and regularly take part.
This study looks at how your immune system responds to CAR-T cell therapy, a treatment that uses your own immune cells to fight certain cancers. By participating, you help researchers learn more about how this therapy affects the body, which could improve care for future patients.
This study looks at blood samples from people with cancer who are starting immunotherapy. Researchers want to find markers that might predict how well the treatment works and whether it could cause side effects.
This study collects blood and tumor samples to understand how well cancer immunotherapy works and what side effects may happen. It mainly helps researchers by checking “immune markers” before treatment starts, while you receive planned immune checkpoint therapy.
Hear when a new Hematological Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.